Vedere Bio II develops next-generation ocular gene therapies using a proprietary, mutation-agnostic optogenetics platform and intravitreally delivered AAV capsids to add or restore light-sensing function downstream of photoreceptors. Its approach targets inherited retinal diseases (IRDs) and geographic atrophy (GA) and is designed to work regardless of the underlying genetic cause or disease stage. The company intends its therapies to enable patients to see stationary and moving objects in bright and dim settings without requiring an external vision-enhancing device. Technology origins include work from UC Berkeley and collaboration with the University of Pennsylvania, and the company was founded by the leadership and research team behind the former Vedere Bio (acquired by Novartis in September 2020). Vedere is headquartered at LabCentral in Cambridge, MA and is funded by a syndicate of life science investors. The Series A financing will support advancement of the platform and therapeutic programs, including the lead program toward IND filing, as well as hiring and research investment.

Total raised

$77M

Funding rounds

1

Latest round

Series A

Latest activity

May 2021